Cure8 research brief
If validated, early bedside ultrasound changes could let clinicians identify within days whether steroids or biologics are working, enabling faster treatment adjustments and potentially avoiding prolonged ineffective therapy.
This study specifically aims to test that idea in outpatients with moderate–to–severe UC starting systemic treatments.
Clinicians treating UC, researchers in IBD imaging and biomarkers, patients with moderate–to–severe ulcerative colitis considering systemic therapy, and teams developing AI imaging tools.
This paper describes a prospective multicentre protocol testing whether early intestinal ultrasound (IUS) changes—especially bowel wall thickness (BWT) measured at day 2 and day 7—predict later need for treatment escalation and clinical outcomes in outpatients with moderate–to–severe ulcerative colitis starting systemic corticosteroids, biologics, or small molecules.
The study will perform serial IUS at baseline, day 2 ±1, day 7 ±1, day 90 ±14 and week 52 ±4 with central blinded reading, and will collect clinical indices, biomarkers, endoscopy, patient‑reported outcomes and multiomics data. Recruitment is planned from March 2026 to February 2028; results are pending.
Strengths noted by authors include standardized IUS protocols, blinded evaluation, integration of endoscopic/biochemical/omics data, and creation of an image repository for future AI work.
Limitations include the observational, nonrandomized design (limiting causal inference), treatment heterogeneity, exclusion of isolated proctitis, and exploratory omics analyses requiring external validation.
Protocol/abstract only — no results reported. Study is observational/nonrandomised and recruitment/planned timelines are given; omics and AI analyses are exploratory and will need external validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Handheld IUS could make noninvasive bowel assessment faster and more accessible for people with IBD, helping with triage and short-term monitoring without immediately resorting to endoscopy or advanced imaging.
AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...
Intestinal ultrasound can assess IBD inflammation without radiation but interpretation varies by operator. Developing AI tools to measure bowel wall thickness and other features could standardize and speed image...
